Solan Headlines

Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies

April 29
13:50 2020
Non-Small Cell Lung Cancer Market Analysis, Market Share, Market Research Report, Leading Companies

Non-Small Cell Lung Cancer- Market Insight, Epidemiology and Market Forecast -2030

LAS VEGAS – April 29, 2020 – The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others.

DelveInsight has introduced a new Market InsightsEpidemiology, and Market Forecast Report on “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030” to its portfolio.

Key Highlights from report are:

  • As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
  • There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
  • The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.
  • One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.

 

 

Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast

 

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

 

The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.

 

Click here to know more on Non-Small Cell Lung Cancer pipeline

 

NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.

Drugs covered in the report are:-

There are several key players robustly involved in developing potential products such as

  • Nazartinib (EGF816)
  • Capmatinib (INC280)
  • Tepmetko (tepotinib)
  • Merestinib
  • JNJ-61186372 (JNJ-6372)
  • Vemurafenib Plus Cobimetinib
  • X-396 (Ensartinib)
  • Tedopi (OSE2101)
  • Selpercatinib (LY3527723/ LOXO-292)
  • SAR408701
  • Braftovi (encorafinib) + Mektovi (binimetinib)
  • PADCEV (enfortumab vedotin/ASG-22ME)
  • Pralsetinib (BLU-667)
  • TAK-788: Canakinumab (ACZ885)
  • Avelumab (Bavencio)
  • Veliparib (ABT-888): Sitravatinib (MGCD516)
  • Tesevatinib
  • Romiplostim: Cabozantinib
  • Sym015
  • AMG 510
  • INCMGA00012 (MGA012)
  • Libtayo (Cemiplimab)
  • Bavituximab
  • M7824 (Bintrafusp alfa)
  • And many others

Key Players covered in the report are:-

  • Novartis Pharmaceuticals
  • Merck KGaA
  • Eli Lilly and Company
  • Janssen Research & Development
  • Hoffmann-La Roche
  • Xcovery
  • BeyondSpring Pharmaceuticals
  • OSE Immunotherapeutics
  • Sanofi
  • Pfizer
  • Astellas Pharma
  • Seattle Genetics
  • Blueprint Medicines Corporation
  • Takeda
  • AbbVie
  • Kadmon Corporation
  • Amgen
  • Symphogen
  • Regeneron Pharmaceuticals
  • Peregrine Pharmaceuticals
  • Avid Bioservices
  • GlaxoSmithKline

And many others

The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.

Market Driver

NSCLC mARKET DRIVER

Market Barrier

NSCLC mARKET barrier

The reasons for buying this report:

  • The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.
  • Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.
  • Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
  • Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
  • Detailed Non-Small Cell Lung Cancer market size by therapies, covering the United States, EU5 and Japan from 2017-2030.
  • Reimbursement scenario and Key Opinion Leader ViewsTable of Contents

 

1.

Key Insights

2.

Executive Summary of NSCLC

3.

SWOT Analysis of NSCLC

4.

Non-Small Cell Lung Cancer Market Overview at a Glance

5.

NSCLC Disease Background and Overview

6.

NSCLC Diagnosis  

7.

Non-Small Cell Lung Cancer Epidemiology and Patient Population

7.1.

The United States Epidemiology

8.

EU-5 Epidemiology

8.1.

Germany

8.2.

France

8.3.

Italy

8.4.

Spain

8.5.

The United Kingdom

9.

Japan Epidemiology

10.

Non-Small Cell Lung Cancer Current Treatment Practices

11.

Guideline of NSCLC

12.

Unmet Needs of NSCLC

13.

Key Endpoints in NSCLC Clinical Trials

14.

Non-Small Cell Lung Cancer Marketed Therapies

14.1.

Key Cross

14.2.

Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)

14.3.

Imfinzi (Durvalumab): AstraZeneca

14.4.

Opdivo (Nivolumab): Bristol-Myers Squibb

14.5.

Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche

14.6.

Keytruda (Pembrolizumab): Merck

14.7.

Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis

14.8.

Tagrisso(Osimertinib): AstraZeneca

14.9.

Lorbrena/Lorviqua (Lorlatinib): Pfizer

14.10.

Vizimpro(Dacomitinib): Pfizer

14.11.

Alunbrig (Brigatinib): Takeda Pharmaceuticals

14.12.

Alecensa (Alectinib): Hoffmann-La Roche

14.13.

Vitrakvi (Larotrectinib): Bayer Healthcare

14.14.

Portrazza (Necitumumab): Eli Lilly

15.

Non-Small Cell Lung Cancer Emerging Therapies

15.1.

Nazartinib (EGF816): Novartis Pharmaceuticals

15.2.

Capmatinib (INC280): Novartis Pharmaceuticals

15.3.

Tepmetko (tepotinib): Merck KGaA

15.4.

Merestinib: Eli Lilly and Company

15.5.

JNJ-61186372 (JNJ-6372): Janssen Research & Development

15.6.

Lazertinib: Yuhan Corporation/ Janssen Research & Development

15.7.

Vemurafenib Plus Cobimetinib: Hoffmann-La Roche

15.8.

X-396 (Ensartinib): Xcovery

15.9.

Plinabulin: BeyondSpring Pharmaceuticals

15.10.

Tedopi (OSE2101): OSE Immunotherapeutics

15.11.

Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company

15.12.

SAR408701: Sanofi

15.13.

Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer

15.14.

PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics

15.15.

Pralsetinib (BLU-667): Blueprint Medicines Corporation

15.16.

TAK-788: Takeda

15.17.

Canakinumab (ACZ885): Novartis Pharmaceuticals

15.18.

Avelumab (Bavencio): Merck KGaA and Pfizer

15.19.

Veliparib (ABT-888): AbbVie

15.20.

Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene

15.21.

Tesevatinib: Kadmon Corporation

15.22.

Romiplostim: Amgen

15.23.

Cabozantinib: Exelixis/Ipsen/Takeda

15.24.

Sym015: Symphogen

15.25.

AMG 510: Amgen

15.26.

INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited

15.27.

Libtayo (Cemiplimab): Regeneron Pharmaceuticals

15.28.

Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc

15.29.

M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA

16.

NSCLC Seven Major Market Analysis

17.

PD-L1—Market Size

18.

BRAF Mutation—Market Size

19.

c-MET Mutation—Market Size

20.

EGFR Mutation—Market Size

21.

ALK-Mutation—Market Size

22.

Market Access and Reimbursement of NSCLC Therapies

23.

Market Drivers of NSCLC

24.

Market Barriers of NSCLC

25.

Appendix

26.

DelveInsight Capabilities

27.

Disclaimer

28.

About DelveInsight

 

Request a Webex Demo to get a walk-through of the report:  https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles